RCUS · Arcus Biosciences, Inc.
$24.59
-5.97% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-7.8
Dividend yield
—
Beta
0.81
Avg volume
1M
Employees
1K
Daily Change %
-5.97%
5 Days Change
-3.94%
10 Days Change
-2.70%
30 Days Change
-0.87%
60 Days Change
-1.49%
Month to Day Change
-4.11%
Year to Day Change
19.56%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RCUS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-08
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$26.00
-0.6% vs priceMorgan Stanley
Equal-Weight$22.00
-15.9% vs priceGoldman Sachs
Buy$34.00
+30.0% vs priceCitigroup
Buy$45.00
+72.1% vs priceBank of America
Neutral$26.00
-0.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | Truist Securities | Reiterates | Buy | $35.00 → $40.00 |
| 2026-08-06 | Wells Fargo | Maintains | Equal-Weight | $23.00 → $26.00 |
| 2026-08-06 | Wedbush | Maintains | Outperform | $41.00 → $43.00 |
| 2026-07-20 | HC Wainwright & Co. | Maintains | Buy | $32.00 → $45.00 |
| 2026-06-04 | LifeSci Capital | Initiates | Outperform | $0.00 → $46.00 |
| 2026-05-11 | Morgan Stanley | Maintains | Equal-Weight | $20.00 → $22.00 |
| 2026-05-07 | Goldman Sachs | Maintains | Buy | $30.00 → $34.00 |
| 2026-04-02 | Wedbush | Maintains | Outperform | $37.00 → $41.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 28 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 15.0% below the 50-day MA ($28.92).
- Price vs 200-day MA: Trading 0.6% below the 200-day MA ($24.74).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.59) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($11.50) and high ($31.57).
RCUS Price Chart
Loading chart for RCUS…
Fundamentals
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.